menu
    • menu
    [{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CYAD-02","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CYAD-211","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Celyad","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ MSD","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ MSD"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CYAD-01","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celyad \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Celyad

    Menu

    Celyad

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces the Publication of Data from Its Phase 1 THINK Study Of CYAD-01

                            Details : CYAD-01 is an autologous CAR T-cell candidate based on the fusion of the NKG2D receptor with CD3ζ. Co-stimulation is ensured by endogenous DAP10. It is being investigated for hematological malignancies, AML, MDS), or multiple myeloma (MM)] and solid tum...

                            Brand Name : CYAD-01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 09, 2023

                            Lead Product(s) : CYAD-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

                            Details : CYAD-101 is an investigational, non-gene edited allogeneic CAR T engineered to co-express chimeric antigen receptor based on NKG2D, that binds to eight stress-induced ligands expressed by a broad range of tumor cells and the novel inhibitory peptide TIM.

                            Brand Name : CYAD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 01, 2022

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

                            Details : Company announced clinical hold on CYAD-101-002 Phase 1b trial for CYAD-101, TCR Inhibitory Molecule based allogeneic NKG2D CAR T cell investigational therapy for treatment of advanced mCRC, due to insufficient information to assess risk to study subject...

                            Brand Name : CYAD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

                            Details : The trial is evaluating TCR Inhibitory Molecule-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with refractory metastat...

                            Brand Name : CYAD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 28, 2022

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Fortress Investment Group

                            Deal Size : $32.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

                            Details : The Company intends to use net proceeds from the private placement to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR ...

                            Brand Name : CYAD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Fortress Investment Group

                            Deal Size : $32.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

                            Details : The recommended dose of 1×109 CYAD-101 cells per infusion will be further evaluated in the expansion cohort of the alloSHRINK trial concurrently with FOLFIRI chemotherapy.

                            Brand Name : CYAD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 18, 2021

                            Lead Product(s) : CYAD-101,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-211,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting an...

                            Details : The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02.

                            Brand Name : CYAD-211

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 04, 2020

                            Lead Product(s) : CYAD-211,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Vi...

                            Details : Two patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73% following tretment with CYAD-101.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 01, 2020

                            Lead Product(s) : CYAD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Celyad

                            Belgium arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYAD-02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

                            Details : Data from this study will provide insights into the pharmacokinetic profile of the four formulations and provide guidance on final formulation selection and dosing for future clinical trials.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 13, 2020

                            Lead Product(s) : CYAD-02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth